Boosted by the worldwide success of its anti-obesity treatments, Novo Nordisk had surpassed LVMH's market capitalization by the end of August 2023. Last year, however, the Danish company had a complicated second half, notably after disappointing clinical results against arch-rival Eli Lilly, and after an outlook deemed too conservative by the market. The share price fell by 10.6% in 2024 and continues to slide in early 2025. By contrast, French luxury group LVMH is coming off a bearish 2024, but rectified the situation at the end of the year, while catching up this week on the back of good figures from its Swiss peer Compagnie Financière Richemont.

Rien ne sert de courir ?

No point in running?

Novo Nordisk increased its losses today after rumors that the US would target Ozempic and Wegowy prices in the next round of Medicare negotiations. At the same time, Donald Trump's threats to Denmark over Greenland increased the risk premium on the small Danish stock market.